Literature DB >> 33637789

Toll-like receptor-9 stimulated plasmacytoid dendritic cell precursors suppress autoimmune neuroinflammation in a murine model of multiple sclerosis.

Hélène Letscher1, Viviane A Agbogan1, Sarantis Korniotis1,2, Pauline Gastineau1, Emmanuel Tejerina1, Christophe Gras1, Jérôme Mégret3, Alison Moe4, William R Drobyski4, Flora Zavala5.   

Abstract

Early innate education of hematopoietic progenitors within the bone marrow (BM) stably primes them for either trained immunity or instead immunoregulatory functions. We herein demonstrate that in vivo or in vitro activation within the BM via Toll-like receptor-9 generates a population of plasmacytoid dendritic cell (pDC) precursors (CpG-pre-pDCs) that, unlike pDC precursors isolated from PBS-incubated BM (PBS-pre-pDCs), are endowed with the capacity to halt progression of ongoing experimental autoimmune encephalomyelitis. CpG activation enhances the selective migration of pDC precursors to the inflamed spinal cord, induces their immediate production of TGF-β, and after migration, of enhanced levels of IL-27. CpG-pre-pDC derived TGF-β and IL-27 ensure protection at early and late phases of the disease, respectively. Spinal cords of CpG-pre-pDC-protected recipient mice display enhanced percentages of host-derived pDCs expressing TGF-β as well as an accumulation of IL-10 producing B cells and of CD11c+ CD11b+ dendritic cells. These results reveal that pDC precursors are conferred stable therapeutic properties by early innate activation within the BM. They further extend to the pDC lineage promising perspectives for cell therapy of autoimmune diseases with innate activated hematopoietic precursor cells.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33637789      PMCID: PMC7910458          DOI: 10.1038/s41598-021-84023-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  55 in total

1.  Development of human plasmacytoid dendritic cells depends on the combined action of the basic helix-loop-helix factor E2-2 and the Ets factor Spi-B.

Authors:  Maho Nagasawa; Heike Schmidlin; Mark G Hazekamp; Remko Schotte; Bianca Blom
Journal:  Eur J Immunol       Date:  2008-09       Impact factor: 5.532

2.  Cutting edge: central nervous system plasmacytoid dendritic cells regulate the severity of relapsing experimental autoimmune encephalomyelitis.

Authors:  Samantha L Bailey-Bucktrout; Sarah C Caulkins; Gwendolyn Goings; Jens A A Fischer; Andrzej Dzionek; Stephen D Miller
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

3.  Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells.

Authors:  M Bauer; V Redecke; J W Ellwart; B Scherer; J P Kremer; H Wagner; G B Lipford
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

Review 4.  Tickets to the brain: role of CCR2 and CX3CR1 in myeloid cell entry in the CNS.

Authors:  Marco Prinz; Josef Priller
Journal:  J Neuroimmunol       Date:  2010-05-31       Impact factor: 3.478

5.  Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells.

Authors:  Vanja Sisirak; Nelly Vey; Nadège Goutagny; Sarah Renaudineau; Marine Malfroy; Sandra Thys; Isabelle Treilleux; Sana Intidhar Labidi-Galy; Thomas Bachelot; Colette Dezutter-Dambuyant; Christine Ménétrier-Caux; Jean-Yves Blay; Christophe Caux; Nathalie Bendriss-Vermare
Journal:  Int J Cancer       Date:  2013-03-08       Impact factor: 7.396

6.  In vivo ablation of plasmacytoid dendritic cells inhibits autoimmunity through expansion of myeloid-derived suppressor cells.

Authors:  Marianna Ioannou; Themis Alissafi; Louis Boon; Dimitrios Boumpas; Panayotis Verginis
Journal:  J Immunol       Date:  2013-02-04       Impact factor: 5.422

7.  Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development.

Authors:  Babacar Cisse; Michele L Caton; Manfred Lehner; Takahiro Maeda; Stefanie Scheu; Richard Locksley; Dan Holmberg; Christiane Zweier; Nicolette S den Hollander; Sarina G Kant; Wolfgang Holter; Anita Rauch; Yuan Zhuang; Boris Reizis
Journal:  Cell       Date:  2008-10-03       Impact factor: 41.582

Review 8.  Two to Tango: Dialog between Immunity and Stem Cells in Health and Disease.

Authors:  Shruti Naik; Samantha B Larsen; Christopher J Cowley; Elaine Fuchs
Journal:  Cell       Date:  2018-11-01       Impact factor: 41.582

9.  A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus.

Authors:  Madhvi Menon; Paul A Blair; David A Isenberg; Claudia Mauri
Journal:  Immunity       Date:  2016-03-08       Impact factor: 31.745

10.  Modulation of Myelopoiesis Progenitors Is an Integral Component of Trained Immunity.

Authors:  Ioannis Mitroulis; Klara Ruppova; Baomei Wang; Lan-Sun Chen; Michal Grzybek; Tatyana Grinenko; Anne Eugster; Maria Troullinaki; Alessandra Palladini; Ioannis Kourtzelis; Antonios Chatzigeorgiou; Andreas Schlitzer; Marc Beyer; Leo A B Joosten; Berend Isermann; Mathias Lesche; Andreas Petzold; Kai Simons; Ian Henry; Andreas Dahl; Joachim L Schultze; Ben Wielockx; Nicola Zamboni; Peter Mirtschink; Ünal Coskun; George Hajishengallis; Mihai G Netea; Triantafyllos Chavakis
Journal:  Cell       Date:  2018-01-11       Impact factor: 41.582

View more
  3 in total

Review 1.  Trained Immunity Contribution to Autoimmune and Inflammatory Disorders.

Authors:  Samanta C Funes; Mariana Rios; Ayleen Fernández-Fierro; María S Di Genaro; Alexis M Kalergis
Journal:  Front Immunol       Date:  2022-04-08       Impact factor: 8.786

Review 2.  Role of Dendritic Cells in Viral Brain Infections.

Authors:  Orianne Constant; Ghizlane Maarifi; Fabien P Blanchet; Philippe Van de Perre; Yannick Simonin; Sara Salinas
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

Review 3.  Toll-Like Receptor Signaling Pathways: Novel Therapeutic Targets for Cerebrovascular Disorders.

Authors:  Rezan Ashayeri Ahmadabad; Zahra Mirzaasgari; Ali Gorji; Maryam Khaleghi Ghadiri
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.